Commentary
Nature Biotechnology 25, 393 - 397 (2007)
doi:10.1038/nbt0407-393
Commercializing cognitive neurotechnology—the ethical terrain
Margaret L Eaton1 & Judy Illes2
- Margaret L. Eaton is at the Graduate School of Business, Stanford University, 518 Memorial Way, Stanford, California 94305-5615, USA. e-mail: illes@stanford.edu
- Judy Illes is at the Stanford Center for Biomedical Ethics, Department of Pediatrics (Medical Genetics), 701 Welch Road, Building A, Suite 1105, Palo Alto, California 94304-5748, USA.
Abstract
Lack of recognition of the ethical, social and policy issues associated with the commercialization of neurotechnology could compromise new ventures in the area.
